𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer

✍ Scribed by Cynthia X. Ma, Matthew J. C. Ellis, Gina R. Petroni, Zhanfang Guo, Shi-rong Cai, Christine E. Ryan, A. Craig Lockhart, Michael J. Naughton, Timothy J. Pluard, Christiana M. Brenin, Joel Picus, Allison N. Creekmore, Tibu Mwandoro, Erin R. Yarde, Jerry Reed, et al

Book ID
118796856
Publisher
Springer US
Year
2012
Tongue
English
Weight
466 KB
Volume
137
Category
Article
ISSN
0167-6806

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

A Phase 1 study of UCN-01 in combination
A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies
✍ Paula M. Fracasso; Kerry J. Williams; Ronald C. Chen; Joel Picus; Cynthia X. Ma; πŸ“‚ Article πŸ“… 2010 πŸ› Springer 🌐 English βš– 451 KB

## Purpose UCN-01 (7-hydroxystaurosporine) is a multi-targeted protein kinase inhibitor that exhibits synergistic activity with DNA-damaging agents in preclinical studies. We conducted a Phase I study to determine the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), pharmacokinetic, and

TBCRC 018: phase II study of iniparib in
TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases
✍ Carey Anders,Allison M. Deal,Vandana Abramson… πŸ“‚ Article πŸ“… 2014 πŸ› Springer US 🌐 English βš– 702 KB

Nearly half of patients with advanced triple negative breast cancer (TNBC) develop brain metastases (BM) and most will also have uncontrolled extracranial disease. This study evaluated the safety and efficacy of iniparib, a small molecule anti-cancer agent that alters reactive oxygen species tumor m